G-29701
G-29701 structure
|
Common Name | G-29701 | ||
|---|---|---|---|---|
| CAS Number | 129-20-4 | Molecular Weight | 324.37400 | |
| Density | 1.241g/cm3 | Boiling Point | 485.6ºC at 760mmHg | |
| Molecular Formula | C19H20N2O3 | Melting Point | 109-111°C | |
| MSDS | Chinese USA | Flash Point | 247.5ºC | |
| Symbol |
GHS07, GHS09 |
Signal Word | Warning | |
|
Bone marrow depression due to mianserin, phenylbutazone, oxyphenbutazone, and chloramphenicol--Part I.
Adverse Drug React. Acute Poisoning Rev. 5(2) , 97-136, (1986)
|
|
|
Bone marrow depression due to mianserin, phenylbutazone, oxyphenbutazone, and chloramphenicol--Part II.
Adverse Drug React. Acute Poisoning Rev. 5(3) , 181-96, (1986)
|
|
|
Disposition and tolerance of suxibuzone in horses.
Equine Vet. J. 31(5) , 411-6, (1999) Suxibuzone (SBZ), a nonsteroidal anti-inflammatory drug, was administered to 6 horses at a dose rate of 7.5 mg/kg bwt by intravenous (i.v.) route. Plasma and synovial fluid concentrations of suxibuzone and its main active metabolites, phenylbutazone (PBZ) and... |
|
|
Pharmacokinetics of phenylbutazone and its metabolite oxyphenbutazone in miniature donkeys.
Am. J. Vet. Res. 62(5) , 673-5, (2001) To describe the pharmacokinetics of phenylbutazone and oxyphenbutazone after IV administration in miniature donkeys.6 clinically normal miniature donkeys.Blood samples were collected before and 5, 10, 20, 30, 45, 60, 90, 120, 180, 240, 300, 360, and 480 minut... |
|
|
Screening, quantification, and confirmation of phenylbutazone and oxyphenbutazone in equine plasma by liquid chromatography-tandem mass spectrometry.
J. Anal. Toxicol. 33(1) , 41-50, (2009) A sensitive liquid chromatographic-tandem mass spectrometric method was developed and validated for screening, quantification, and confirmation of phenylbutazone and oxyphenbutazone in equine plasma. Analytes were recovered from plasma by liquid-liquid extrac... |
|
|
Phospholipase A2 as a target protein for nonsteroidal anti-inflammatory drugs (NSAIDS): crystal structure of the complex formed between phospholipase A2 and oxyphenbutazone at 1.6 A resolution.
Biochemistry 43(46) , 14577-83, (2004) Phospholipase A(2) (PLA(2); EC 3.1.1.4) is a key enzyme involved in the production of proinflammatory mediators known as eicosanoids. The binding of the substrate to PLA(2) occurs through a well-formed hydrophobic channel. To determine the viability of PLA(2)... |
|
|
Direct injection HPLC method for the determination of phenylbutazone and oxyphenylbutazone in serum using a semipermeable surface column.
J. Pharm. Biomed. Anal. 16(2) , 287-93, (1997) A direct injection HPLC method has been developed for the determination of phenylbutazone and its active metabolite oxyphenylbutazone in serum using a semipermeable surface (SPS) column. The method is easy to perform and requires 20 microliters of a filtered ... |
|
|
Determination of binding conformations of drugs to human serum albumin by transferred nuclear overhauser effect measurements and conformational analyses using high-temperature molecular dynamics calculations.
J. Pharm. Sci. 87 , 379-386, (1998) The binding conformations of oxyphenbutazone (OXY), Nepsilon-dansyl-L-lysine (DNS-LYS), and furosemide (FU) to human serum albumin (HSA) have been investigated by molecular dynamics (MD) calculations and transferred nuclear Overhauser effect (TRNOE) measureme... |
|
|
Structural and ligand-binding properties of serum albumin species interacting with a biomembrane interface.
J. Pharm. Sci. 96(11) , 3117-24, (2007) In the process of drug development, preclinical testing using experimental animals is an important aspect, for verification of the efficacy and safety of a drug. Serum albumin is a major binding protein for endogenous and exogenous ligands and regulates their... |
|
|
Systemic treatment of sarcoidosis.
Ocul. Immunol. Inflamm. 19(2) , 145-50, (2011) To compare the evidence base and systemic treatment strategies for sarcoidosis.Medline and EMBASE literature search on "sarcoidosis AND treatment", "sarcoidosis AND uveitis AND treatment", and "sarcoidosis AND eye AND treatment". The search was limited to ran... |